Catherine S. Grasso

12.6k citations

35 papers · 3.2k indexed · 2 hit papers · h-index 18

Molecular Biology top 5%
Cancer Research top 1%
Oncology top 5%
Pulmonary and Respiratory Medicine top 5%
Immunology top 10%

Co-authors: Christopher Lee Mark Sharlow Xuhong Cao Arul M. Chinnaiyan Nallasivam Palanisamy J. Chad Brenner Christopher A. Maher Antoni Ribas
Topics: Cancer Genomics and Diagnostics (8 papers)Cancer Immunotherapy and Biomarkers (7 papers)Prostate Cancer Treatment and Research (6 papers)
Cited by: Cancer Research Molecular Biology Oncology
Journals: Proceedings of the National Academy of Sciences Journal of Clinical Investigation Nature Medicine
Partner nations: United States United Kingdom Canada

In The Last Decade

Catherine S. Grasso

34 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression

2011 815 citations Saravana M. Dhanasekaran, Qi Cao et al. profile →
Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress

2018 583 citations Jennifer Tsoi, Lídia Robert et al. Cancer Cell profile →

Peers

Countries citing papers authored by Catherine S. Grasso

Since Specialization

Citations

This map shows the geographic impact of Catherine S. Grasso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine S. Grasso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine S. Grasso more than expected).

Fields of papers citing papers by Catherine S. Grasso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine S. Grasso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine S. Grasso. The network helps show where Catherine S. Grasso may publish in the future.

Co-authorship network of co-authors of Catherine S. Grasso

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine S. Grasso. A scholar is included among the top collaborators of Catherine S. Grasso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine S. Grasso. Catherine S. Grasso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PAK4 inhibition improves PD1 blockade immunotherapy in prostate cancer by increasing immune infiltration 2022 ·Cancer Letters ·(unknown),Sungyong You,Yanping Wang,Patrick Tamukong,Michael J. Quist,Catherine S. Grasso,Hyung L. Kim	16
2	Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti–PD-1 therapy 2021 ·Journal of Clinical Investigation ·Yeon Joo Kim,Katherine M. Sheu,Jennifer Tsoi,Gabriel Abril-Rodríguez,Egmidio Medina,Catherine S. Grasso,Davis Y. Torrejon,Ameya S. Champhekar,Kevin Litchfield,Charles Swanton,Daniel E. Speiser,Philip O. Scumpia,Alexander Hoffmann,Thomas G. Graeber,Cristina Puig-Saus,Antoni Ribas	40
3	Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential 2020 ·BMC Cancer ·(unknown),Sungyong You,(unknown),Minhyung Kim,Junhee Yoon,Sandy Liu,Xinmin Li,Lorna Kwan,Jennelle C. Hodge,Michael J. Quist,Catherine S. Grasso,Michael Lewis,Beatrice S. Knudsen,Michael R. Freeman,Isla P. Garraway	10
4	Copy number alterations are associated with metastatic-lethal progression in prostate cancer 2020 ·Prostate Cancer and Prostatic Diseases ·Xiaoyu Wang,Catherine S. Grasso,Kristina M. Jordahl,Suzanne Kolb,Yaw A. Nyame,Jonathan L. Wright,Elaine A. Ostrander,Dean A. Troyer,Raymond Lance,Ziding Feng,James Y. Dai,Janet L. Stanford	11
5	Interleukin 32 expression in human melanoma 2019 ·Journal of Translational Medicine ·Helicia Paz,Jennifer Tsoi,Anusha Kalbasi,Catherine S. Grasso,William H. McBride,Dörthe Schaue,Lisa H. Butterfield,Deena M. Maurer,Antoni Ribas,Thomas G. Graeber,James S. Economou	12
6	Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma 2019 ·Nature Medicine ·Antoni Ribas,Donald P. Lawrence,Victoria Atkinson,Sachin Agarwal,Wilson H. Miller,Matteo S. Carlino,Rosalie Fisher,Georgina V. Long,F. Stephen Hodi,Jennifer Tsoi,Catherine S. Grasso,Bijoyesh Mookerjee,Qing Zhao,Razi Ghori,Blanca Homet Moreno,Nageatte Ibrahim,Omid Hamid	230
7	Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stressbreakdown → 2018 ·Cancer Cell ·Jennifer Tsoi,Lídia Robert,Kim H.T. Paraiso,C. Galvan,Katherine M. Sheu,Johnson Lay,Deborah J. Wong,Mohammad Atefi,Roksana Shirazi,Xiaoyan Wang,Daniel Braas,Catherine S. Grasso,Nicolaos Palaskas,Antoni Ribas,Thomas G. Graeber	583
8	Abstract CT008: A pilot trial of the combination of transgenic NY-ESO-1-reactive adoptive cellular therapy with dendritic cell vaccination with or without ipilimumab in patients with sarcoma and melanoma 2018 ·Cancer Research ·Theodore S. Nowicki,Beata Berent-Maoz,Rong Huang,Xiaoyan Wang,Gardenia Cheung-Lau,Paula Kaplan‐Lefko,Paula Cabrera,(unknown),Ignacio Baselga-Carretero,Catherine S. Grasso,Siwen Hu‐Lieskovan,Bartosz Chmielowski,Begoña Comı́n-Anduix,Arun S. Singh,Antoni Ribas	2
9	Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities 2017 ·Molecular and Cellular Endocrinology ·(unknown),(unknown),Xiaoyong Fu,Li Zhao,Catherine S. Grasso,Michael J. Quist,Joseph Lewis,(unknown),Alan Zwart,(unknown),Balázs Győrffy,Luciane R. Cavalli,Rebecca B. Riggins	21
10	Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors 2015 ·Molecular Cancer Research ·Andi K. Cani,Daniel H. Hovelson,Andrew S. McDaniel,Seth Sadis,(unknown),Venkata Yadati,Anmol M. Amin,(unknown),Santhoshi Bandla,Paul Williams,Kate Rhodes,Chia‐Jen Liu,Michael J. Quist,Daniel R. Rhodes,Catherine S. Grasso,Celina G. Kleer,Scott A. Tomlins	97
11	Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing Data 2014 ·Journal of Molecular Diagnostics ·Catherine S. Grasso,Timothy Butler,Katherine Rhodes,Michael J. Quist,Tanaya Neff,S. S. Moore,Scott A. Tomlins,(unknown),Carol Beadling,Mark T. Andersen,Christopher L. Corless	85
12	HRAS mutations are frequent in inverted urothelial neoplasms 2014 ·Human Pathology ·Andrew S. McDaniel,Yali Zhai,Kathleen R. Cho,Saravana M. Dhanasekaran,Jeffrey S. Montgomery,Ganesh S. Palapattu,Javed Siddiqui,Todd M. Morgan,Ajjai Alva,Alon Z. Weizer,Cheryl T. Lee,Arul M. Chinnaiyan,Michael J. Quist,Catherine S. Grasso,Scott A. Tomlins,Rohit Mehra	27
13	Outlier Kinase Expression by RNA Sequencing as Targets for Precision Therapy 2013 ·Cancer Discovery ·Vishal Kothari,(unknown),Sunita Shankar,Shanker Kalyana‐Sundaram,Lidong Wang,(unknown),Pankaj Vats,Catherine S. Grasso,Dan R. Robinson,Yi-Mi Wu,Xuhong Cao,Diane M. Simeone,Arul M. Chinnaiyan,Chandan Kumar‐Sinha	29
14	Detection of Somatic Copy Number Alterations in Cancer Using Targeted Exome Capture Sequencing 2011 ·Neoplasia ·Robert J. Lonigro,Catherine S. Grasso,Dan R. Robinson,Xiaojun Jing,Yi-Mi Wu,Xuhong Cao,Michael J. Quist,Scott A. Tomlins,Kenneth J. Pienta,Arul M. Chinnaiyan	55
15	The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer 2010 ·Oncogene ·Jian Yu,Qi Cao,Longtao Wu,(unknown),(unknown),(unknown),Catherine S. Grasso,Xuhong Cao,(unknown),Sooryanarayana Varambally,(unknown),Nallasivam Palanisamy,Farida Latif,(unknown),(unknown)	66
16	Computational Analysis of Sequence Selection Mechanisms 2004 ·Structure ·(unknown),Catherine S. Grasso,Jon Kleinberg,Ron Elber	12
17	Combining partial order alignment and progressive multiple sequence alignment increases alignment speed and scalability to very large alignment problems 2004 ·Bioinformatics ·Catherine S. Grasso,Christopher Lee	93
18	GENOME-WIDE DETECTION OF ALTERNATIVE SPLICING IN EXPRESSED SEQUENCES USING PARTIAL ORDER MULTIPLE SEQUENCE ALIGNMENT GRAPHS 2003 ·PubMed ·Catherine S. Grasso,Barmak Modrek,Yi Xing,(unknown)	16
19	Multiple sequence alignment using partial order graphs 2002 ·Bioinformatics ·Christopher Lee,Catherine S. Grasso,Mark Sharlow	399
20	Symbionticism and Complex Adaptive Systems I: Implications of Having Symbiosis Occur in Nature. 1996 ·Jason M. Daida,Catherine S. Grasso,Stephen A. Stanhope,Steven J. Ross	13

About Catherine S. Grasso

Catherine S. Grasso is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 35 papers that have together received 3.2k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Prostate Cancer Treatment and Research (6 papers). The work is most often cited by research in Cancer Research (1.4k citations), Molecular Biology (2.2k citations) and Oncology (652 citations). Catherine S. Grasso has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Christopher Lee, Mark Sharlow, Xuhong Cao, Arul M. Chinnaiyan, Nallasivam Palanisamy, J. Chad Brenner, Christopher A. Maher, Antoni Ribas, Jennifer Tsoi and Xiaojun Jing. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact